Results 11 to 20 of about 355,709 (346)

Liquid Biopsy and NSCLC [PDF]

Lung Cancer Management, 2016
In the era of high-throughput molecular screening and personalized medicine, difficulty in determining whether cancer mutations are truly 'actionable' remains a gray zone in NSCLC. The most important prerequisite to perform such investigations is the tumor tissue retrieval via biopsy at diagnosis and after occurrence of resistance.
Trombetta, D., Sparaneo, A., Fabrizio, F. P., Muscarella, L. A.   +3 more
openaire   +2 more sources

The possibilities of combination immunotherapy with radiation therapy for the treatment of patients with inoperable locally advanced non-small cell lung cancer

Исследования и практика в медицине, 2021
Currently, lung cancer is a global problem and public health issue in the world. Chemoradiotherapy remains the optimal method in the treatment of patients with unresectable non-small cell lung cancer (NSCLC).
E. I. Smolenov, G. V. Afonin, V. S. Usachev, D. D. Kudryavtsev, I. V. Kolobaev, S. A. Ivanov   +5 more
doaj   +1 more source

Fuzheng Kang-Ai decoction enhances the effect of Gefitinib-induced cell apoptosis in lung cancer through mitochondrial pathway

Cancer Cell International, 2020
Background Our previous clinical study has shown that Chinese herbal medicine (CHM) Fuzheng Kang-Ai (FZKA) decoction is effective in treating advanced lung cancer patients through prolonging the drug resistance to Gefitinib (GFTN).
Sumei Wang, Zhiwei Peng, Wenjuan Li, Shunqin Long, Shujing Xiao, Wanyin Wu   +5 more
doaj   +1 more source

Non-small cell lung cancer (NSCLC): A review of risk factors, diagnosis, and treatment

Medicine, 2023
Lung cancer remains the leading cause of cancer deaths. Non-small cell lung cancer (NSCLC) is the most frequent subtype of lung cancer. Surgery, radiation, chemotherapy, immunotherapy, or molecularly targeted therapy is used to treat NSCLC. Nevertheless,
Yaser Alduais, Haijun Zhang, Fangjing Fan, J. Chen, B. Chen   +4 more
semanticscholar   +1 more source

Angiogenesis Inhibitors in NSCLC [PDF]

International Journal of Molecular Sciences, 2017
Angiogenesis is a complex biological process that plays a relevant role in sustaining the microenvironment, growth, and metastatic potential of several tumors, including non-small cell lung cancer (NSCLC). Bevacizumab was the first angiogenesis inhibitor approved for the treatment of patients with advanced NSCLC in combination with chemotherapy ...
Nicola Normanno, Maria Carmela Piccirillo, Guido Carillio, Francesco Perrone, Gennaro Daniele, Alessandro Morabito, Gaetano Rocco, Raffaele Costanzo, Agnese Montanino, Anna Manzo, Claudia Sandomenico   +10 more
openaire   +3 more sources

Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC.

Cancer Discovery, 2023
Molecular modifiers of KRAS G12C inhibitor (KRAS G12Ci) efficacy in advanced KRAS G12C-mutant NSCLC are poorly defined. In a large unbiased clinico-genomic analysis of 424 NSCLC patients, we identified and validated co-alterations in KEAP1, SMARCA4 and ...
M. Negrão, Haniel A Araujo, G. Lamberti, Alissa J Cooper, Neal S Akhave, Teng Zhou, Lukas Delasos, J. K. Hicks, M. Aldea, G. Minuti, J. Hines, J. Aredo, Michael J Dennis, T. Chakrabarti, S. Scott, P. Bironzo, M. Scheffler, P. Christopoulos, A. Stenzinger, J. Riess, So Yeon Kim, S. Goldberg, Mingjia Li, Qi Wang, Yun Qing, Y. Ni, Minh Truong Do, Richard Lee, B. Ricciuti, J. Alessi, Jing Wang, B. Resuli, L. Landi, Shu-Chi Tseng, M. Nishino, S. Digumarthy, W. Rinsurongkawong, Vadeerat Rinsurongkawong, A. Vaporciyan, G. Blumenschein, Jianjun Zhang, D. Owen, C. Blakely, G. Mountzios, C. Shu, C. Bestvina, M. Garassino, K. Marrone, J. Gray, S. Patel, A. Cummings, H. Wakelee, J. Wolf, G. Scagliotti, F. Cappuzzo, F. Barlesi, P. Patil, L. Drusbosky, D. Gibbons, F. Meric-Bernstam, J. Lee, J. Heymach, David S. Hong, R. Heist, M. Awad, F. Skoulidis   +65 more
semanticscholar   +1 more source

Experience of treatment of a patient with non-small cell lung cancer with met exon 14 skipping

Медицинский совет, 2021
Personalized therapy is starting to play an increasing role in modern approaches to the treatment of oncological diseases. The previously existing uniform standard for each malignant disease is expanded with new options and treatment possibilities ...
M. O. Mandrina, V. V. Breder, M. V. Ivanov, A. A. Lebedeva, V. V. Gorbatsevich, K. K. Laktionov, P. V. Kononets   +6 more
doaj   +1 more source

Structure-based classification predicts drug response in EGFR-mutant NSCLC

Nature, 2021
Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18–21 and are established driver mutations in non-small cell lung cancer (NSCLC)1–3.
J. Robichaux, X. Le, R. Vijayan, J. K. Hicks, S. Heeke, Y. Elamin, Heather Y. Lin, H. Udagawa, F. Skoulidis, H. Tran, S. Varghese, Junqin He, Fahao Zhang, M. Nilsson, Lemei Hu, A. Poteete, W. Rinsurongkawong, Xiaoshan Zhang, C. Ren, Xiaoke Liu, L. Hong, Jianjun Zhang, L. Diao, R. Madison, A. Schrock, J. Saam, V. Raymond, B. Fang, Jing Wang, M. Ha, J. Cross, J. Gray, J. Heymach   +32 more
semanticscholar   +1 more source

Smoking‐Induced M2‐TAMs, via circEML4 in EVs, Promote the Progression of NSCLC through ALKBH5‐Regulated m6A Modification of SOCS2 in NSCLC Cells

Advancement of science, 2023
Lung cancer is a commonly diagnosed disease worldwide, with non‐small cell lung cancers (NSCLCs) accounting for ≈ 85% of cases. Cigarette smoke is an environmental exposure promoting progression of NSCLC, but its role is poorly understood.
Cheng Cheng, Peiwen Wang, Yi Yang, Xuan Du, Haibo Xia, Jinyuan Liu, Lu Lu, Hao Wu, Qizhan Liu   +8 more
semanticscholar   +1 more source

Therapeutic Sequencing in ALK+ NSCLC [PDF]

Pharmaceuticals, 2021
Anaplastic lymphoma kinase-rearranged non-small-cell lung cancer (ALK+ NSCLC) is a model disease for the use of targeted pharmaceuticals in thoracic oncology. Due to higher systemic and intracranial efficacy, the second-generation ALK tyrosine kinase inhibitors (TKI) alectinib and brigatinib have irrevocably displaced crizotinib as standard first-line ...
Mei Elsayed, Petros Christopoulos
openaire   +4 more sources